Pasithea Therapeutics KTTA Stock
Pasithea Therapeutics Price Chart
Pasithea Therapeutics KTTA Financial and Trading Overview
| Pasithea Therapeutics stock price | 6.3 USD |
| Previous Close | 0.45 USD |
| Open | 0.46 USD |
| Bid | 0 USD x 2200 |
| Ask | 0 USD x 900 |
| Day's Range | 0.44 - 0.47 USD |
| 52 Week Range | 0.31 - 1.54 USD |
| Volume | 69.86K USD |
| Avg. Volume | 85.95K USD |
| Market Cap | 12.1M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -13.74 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2 USD |
KTTA Valuation Measures
| Enterprise Value | -17427472 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.6523944 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 24.872396 |
| Price/Book (mrq) | 0.30921227 |
| Enterprise Value/Revenue | -35.818 |
| Enterprise Value/EBITDA | 1.106 |
Trading Information
Pasithea Therapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -54.60% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.54 USD |
| 52 Week Low | 0.31 USD |
| 50-Day Moving Average | 0.39 USD |
| 200-Day Moving Average | 0.73 USD |
KTTA Share Statistics
| Avg. Volume (3 month) | 85.95K USD |
| Avg. Daily Volume (10-Days) | 301.5K USD |
| Shares Outstanding | 26.13M |
| Float | 15.46M |
| Short Ratio | 1.96 |
| % Held by Insiders | 26.37% |
| % Held by Institutions | 3.56% |
| Shares Short | 58.94K |
| Short % of Float | 0.27% |
| Short % of Shares Outstanding | 0.22% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -3278.12% |
| Gross Margin | 76.73% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -21.41% |
| Return on Equity (ttm) | -35.70% |
Income Statement
| Revenue (ttm) | 486.56K USD |
| Revenue Per Share (ttm) | 0.02 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -15760915 USD |
| Net Income Avi to Common (ttm) | -15908681 USD |
| Diluted EPS (ttm) | -0.58 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 29.91M USD |
| Total Cash Per Share (mrq) | 1.15 USD |
| Total Debt (mrq) | 729.56K USD |
| Total Debt/Equity (mrq) | 1.86 USD |
| Current Ratio (mrq) | 14.661 |
| Book Value Per Share (mrq) | 1.498 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -15384233 USD |
| Levered Free Cash Flow (ttm) | -10403912 USD |
Profile of Pasithea Therapeutics
| Country | United States |
| State | FL |
| City | Miami Beach |
| Address | 1111 Lincoln Road |
| ZIP | 33139 |
| Phone | 702 514 4174 |
| Website | https://www.pasithea.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 15 |
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers. Its lead product candidate PAS-004, a next-generation mitogen-activated protein kinase, or MEK inhibitor designed to be macrocyclic for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 and Noonan syndrome, as well as lamin A/C cardiomyopathy and oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; PAS-002, for the treatment multiple sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Q&A For Pasithea Therapeutics Stock
What is a current KTTA stock price?
Pasithea Therapeutics KTTA stock price today per share is 6.3 USD.
How to purchase Pasithea Therapeutics stock?
You can buy KTTA shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Pasithea Therapeutics?
The stock symbol or ticker of Pasithea Therapeutics is KTTA.
Which industry does the Pasithea Therapeutics company belong to?
The Pasithea Therapeutics industry is Biotechnology.
How many shares does Pasithea Therapeutics have in circulation?
The max supply of Pasithea Therapeutics shares is 1.04M.
What is Pasithea Therapeutics Price to Earnings Ratio (PE Ratio)?
Pasithea Therapeutics PE Ratio is now.
What was Pasithea Therapeutics earnings per share over the trailing 12 months (TTM)?
Pasithea Therapeutics EPS is -13.74 USD over the trailing 12 months.
Which sector does the Pasithea Therapeutics company belong to?
The Pasithea Therapeutics sector is Healthcare.
Pasithea Therapeutics KTTA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17019.88 USD — |
+0.59
|
5.94B USD — | 16917.51 USD — | 17032.66 USD — | — - | 5.94B USD — |
| NASDAQ HealthCare IXHC | 978.74 USD — |
-1.03
|
— — | 973.64 USD — | 990.74 USD — | — - | — — |
- {{ link.label }} {{link}}